Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012

Publisher： John Wiley & Sons Inc

E-ISSN： 1537-2995|55|S2|S36-S46

ISSN： 0041-1132

Source： TRANSFUSION, Vol.55, Iss.S2, 2015-07, pp. : S36-S46

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Do immune complexes play a role in hemolytic sequelae of intravenous immune globulin?

By  

TRANSFUSION, Vol. 55, Iss. S2, 2015-07 ,pp. : S86-S89

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hemolytic events after the administration of lyophilized versus liquid immune globulin: an analysis of a single manufacturer's safety database

By  

TRANSFUSION, Vol. 55, Iss. 8, 2015-08 ,pp. : 1847-1854

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hemolytic adverse events with immune globulin products: product factors and patient risks

By  

TRANSFUSION, Vol. 55, Iss. S2, 2015-07 ,pp. : S2-S5

John Wiley & Sons Inc

Access to resources Recommend Favorite

Polyvalent immune globulin usage by indication in the United States, 2012: a quantitative analysis of the use of polyvalent immune globulin (intravenous and subcutaneous) by medical indication in the United States in 2012

By  

TRANSFUSION, Vol. 55, Iss. S2, 2015-07 ,pp. : S6-S12

John Wiley & Sons Inc

Access to resources Recommend Favorite

The role of inflammation in intravenous immune globulin–mediated hemolysis

By  

TRANSFUSION, Vol. 55, Iss. S2, 2015-07 ,pp. : S65-S73

John Wiley & Sons Inc

Access to resources Recommend Favorite